10-QPeriod: Q3 FY2024

BIOGEN INC. Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 30, 2024For Securities:BIIB

Summary

Biogen Inc. reported net income of $388.5 million, or $2.66 per diluted share, for the third quarter of 2024, a significant improvement from a net loss of $68.1 million in the same period last year. This turnaround was driven by a substantial decrease in total costs and expenses, including lower R&D and SG&A expenses, partly due to the phasing out of acquisition-related equity compensation costs recognized in the prior year. Total revenue saw a slight decrease of 2.5% to $2.47 billion, mainly impacted by a 9.1% decline in Multiple Sclerosis (MS) product revenue due to increased competition, particularly for TYSABRI and TECFIDERA. The company successfully completed the acquisition of HI-Bio for $1.15 billion in July 2024, adding felzartamab to its pipeline for severe immune-mediated diseases. This strategic move is expected to bolster Biogen's immunology and rare disease portfolios. While overall MS revenue continues to face challenges from generic competition and shifting patient preferences towards higher efficacy therapies, the Rare Disease segment showed strong growth, primarily driven by the initial sales of SKYCLARYS, acquired through the Reata transaction in late 2023. Biogen's financial position remains solid with cash and cash equivalents increasing to $1.7 billion. The company generated $2.1 billion in operating cash flow for the first nine months of the year. Despite ongoing competitive pressures in key therapeutic areas, Biogen's focus on pipeline advancement and strategic acquisitions positions it to navigate the evolving biopharmaceutical landscape. Investors should monitor the performance of newer products like SKYCLARYS and the progress of pipeline assets such as felzartamab, while also considering the continued challenges in the MS segment.

Financial Highlights

49 data points
Beta

Revenue

$2.47B

74.1% Gross Margin

Net Income

$388.50M

15.8% Net Margin

EPS (Diluted)

$2.66

Total Assets

$28.31B

Cash & Equivalents

$1.70B

Free Cash Flow

$900.60M

Financial Statements
Beta
Revenue$2.47B
Cost of Revenue$638.70M
Gross Profit$1.83B
SG&A Expenses$588.40M
Operating Expenses$2.01B
Interest Expense$59.80M
Net Income$388.50M
EPS (Basic)$2.67
EPS (Diluted)$2.66
Shares Outstanding (Basic)145.70M
Shares Outstanding (Diluted)146.10M

Key Highlights

  • 1Biogen reported a strong Q3 2024 with net income of $388.5 million ($2.66/share), a significant turnaround from a net loss of $68.1 million in Q3 2023.
  • 2Total revenue decreased slightly by 2.5% to $2.47 billion, impacted by a 9.1% decline in Multiple Sclerosis (MS) revenue due to competition.
  • 3Rare Disease revenue increased by 10.0%, driven by $102.3 million in SKYCLARYS sales in Q3 2024.
  • 4The company completed the acquisition of HI-Bio for $1.15 billion in July 2024, strengthening its immunology pipeline with felzartamab.
  • 5Total costs and expenses decreased by 24.6% to $2.01 billion, primarily due to lower R&D and SG&A expenses compared to the prior year's acquisition-related costs.
  • 6Cash and cash equivalents increased to $1.7 billion as of September 30, 2024, with strong operating cash flow generation of $2.1 billion for the first nine months of the year.

Frequently Asked Questions

Biogen reported a significant improvement in Q3 2024, with a net income of $388.5 million ($2.66 per diluted share), compared to a net loss of $68.1 million ($0.47 per diluted share) in Q3 2023. This was driven by a substantial decrease in total costs and expenses, more than offsetting a slight 2.5% decrease in total revenue to $2.47 billion.

The overall revenue decrease was primarily due to a 9.1% decline in Multiple Sclerosis (MS) product revenue, which fell to $1.05 billion from $1.16 billion year-over-year. This decline is attributed to increased competition, generic entrants for products like TECFIDERA, and a decrease in demand for Interferon-based therapies as patients shift to higher efficacy treatments. Revenue from contract manufacturing, royalty, and other sources also decreased.

Biogen completed the acquisition of HI-Bio for $1.15 billion in July 2024, funded by cash on hand. This acquisition adds felzartamab to Biogen's pipeline, targeting severe immune-mediated diseases. While the acquisition itself did not have a significant impact on revenue in Q3 2024, it represents a strategic investment in future growth areas. The associated equity-based compensation for HI-Bio employees was approximately $42.5 million in R&D and $13.9 million in SG&A for Q3 2024.

Total costs and expenses decreased by 24.6% to $2.01 billion in Q3 2024. R&D expenses decreased by 26.3% due to a significant factor being the absence of the large equity-based compensation expense related to the Reata acquisition in the prior year ($197 million). Cost-reduction measures from the 'Fit for Growth' program also contributed. SG&A expenses similarly decreased by 25.3%, largely due to the year-over-year reduction in acquisition-related equity compensation costs (Reata: $196.4 million in prior year).